Guildford, UK and Framingham, MA, September 9th, 2020 – IDBS announced today that it has released a fully-featured integration between the E-WorkBook electronic laboratory notebook (ELN) and SCIEX Analyst® Software, expanding IDBS’s existing family of integrations.
This new integration strengthens IDBS’ existing preclinical capabilities by seamlessly transferring data, enabling increased regulatory compliance and improved throughput.
In response to the call for improved preclinical workflows in regulated environments, IDBS leveraged its existing bioanalytical experience, coupled with customer and market inputs, to develop the integration. As part of the preclinical process design, the integration delivers the ability to seamlessly upload injection sequences and retrieve raw and processed results, providing a tamper-proof method of data exchange with a full audit trail of actions. This innovation allows customers to proactively conform to regulatory guidelines.
Christian Marcazzo, General Manager at IDBS said, “The addition of the new SCIEX Analyst integration component complements IDBS’ deep domain expertise, bolstering E-WorkBook’s support of end-to-end workflows. This capability strengthens our solution and supports our growth strategy to partner with like-minded organizations to enhance our enterprise R&D data management platform.”
Dominic Gostick, Vice President & GM LCMS at SCIEX said, “Our work with IDBS offers E-WorkBook customers the tools to seamlessly integrate with the SCIEX Analyst platform, enabling streamlining of important preclinical processes. We look forward to our continued collaboration with IDBS and their product updates in the near future.”
The E-WorkBook platform is both ISO 9001 and ISO 27001 certified. IDBS achieved the SOC 2 certification of data quality in 2019 and has over 35 validated GxP customers, 30% of whom have their solutions deployed in a validated cloud environment. IDBS will continue to deepen their partnership with SCIEX and other Danaher companies as part of a continuing initiative to deliver the next-generation biopharmaceutical working environment.
IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high-tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.
IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high-tech materials and consumer products.
Founded in 1989, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide, and became a member of the Danaher family of global life science and technology innovators in 2017. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and the Queen’s Award for International Trade in 2011. Additional information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.
SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.
Today, as part of the Danaher family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.
That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.